论文信息 - Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years. - 字舞流文

Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years.

K. Miskowiak | H. Ehrenreich | A. Neubauer

[1] L. Held,et al. Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants. , 2020, JAMA.

[2] P. Heagerty,et al. Erythropoietin in Preterm Infants. Reply. , 2020, New England Journal of Medicine.

[3] Phuong T. Vu,et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. , 2020, The New England journal of medicine.

[4] L. Held,et al. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. , 2016, JAMA.

[5] A. Neubauer,et al. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants , 2010, Annals of neurology.